Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (265 ops.)
Latest filing published 22 Oct 2026 for Rapport Therapeutics, Inc., €89k.
Filing timeline
BuySalePaul M. Silva
First 200 filings with a declared amount
Insider track record
Disclosed buys
1
Disclosed sells
265
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Paul M. Silva: trading record in brief
Filings by Paul M. Silva span 2 companies, the busiest being Vertex Pharmaceuticals INC / MA and Rapport Therapeutics, Inc. We count 417 filings; the first trade dates from 18 November 2008 and the latest from 22 October 2026.
Market trades split into 1 purchase (€89k) and 265 sales (€43.5M). Netting one side against the other leaves €43.4M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 27 share grants and 123 option exercises. So far in 2026, the count stands at 1 purchase and no sales.
The record was last updated on 22 October 2026 with an open-market purchase (€89k) in Rapport Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Paul M. Silva
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations413 total
3,680 shares@ US$27.0750.0071% mcap100.0% of flowCommon StockSEC:0001193125-26-429075:0
Canonical exit: 20 Jan 2027 (T+90)
2,218 shares@ US$212.420.8% of flowCommon StockSEC:0001209191-21-015849:0
1,026 shares@ US$210.130.4% of flowCommon StockSEC:0001209191-21-015849:1
610 shares@ US$211.450.2% of flowCommon StockSEC:0001209191-21-015849:2
915 shares@ US$212.510.4% of flowCommon StockSEC:0001209191-21-015849:3
231 shares@ US$213.120.1% of flowCommon StockSEC:0001209191-21-015849:4
864 shares@ US$217.570.3% of flowCommon StockSEC:0001209191-21-014749:0
244 shares@ US$211.800.1% of flowCommon StockSEC:0001209191-21-014749:1
452 shares@ US$213.120.2% of flowCommon StockSEC:0001209191-21-014749:2
258 shares@ US$214.320.1% of flowCommon StockSEC:0001209191-21-014749:3
126 shares@ US$216.250.0% of flowCommon StockSEC:0001209191-21-014749:4
2,740 shares@ US$211.751.1% of flowCommon StockSEC:0001209191-21-012355:0
584 shares@ US$210.050.2% of flowCommon StockSEC:0001209191-21-012355:1
2,343 shares@ US$211.820.9% of flowCommon StockSEC:0001209191-21-012355:2
1,368 shares@ US$212.620.5% of flowCommon StockSEC:0001209191-21-012355:3
1,288 shares@ US$210.450.5% of flowCommon StockSEC:0001209191-21-010739:0
210 shares@ US$211.320.1% of flowCommon StockSEC:0001209191-21-010739:1
651 shares@ US$214.160.3% of flowCommon StockSEC:0001209191-21-010125:0
4,220 shares0Common StockSEC:0001209191-21-008149:0
3,226 shares0Common StockSEC:0001209191-21-008149:1
3,634 shares0Common StockSEC:0001209191-21-008149:2
466 shares@ US$187.530.3% of flowCommon StockSEC:0001209191-20-045942:0
612 shares@ US$155.570.4% of flowCommon StockSEC:0001209191-20-045942:1
420 shares@ US$270.120.5% of flowCommon StockSEC:0001209191-20-045942:2
211 shares@ US$270.920.2% of flowCommon StockSEC:0001209191-20-045942:3
25 of 413 declarations
